The role of interleukin 6 in the pathogenesis and therapy of Castleman disease – an immunologist's perspective
Authors:
Tomáš Milota; Zuzana Střížová; Marta Sobotková; Jiřina Bartůňková
Authors‘ workplace:
Ústav imunologie 2. LF UK a FN Motol, Praha
Published in:
Čas. Lék. čes. 2023; 162: 106-111
Category:
Review Article
Overview
Castleman disease (CD) is a heterogeneous group of diseases characterized by lymphadenopathy and systemic inflammatory manifestations. CD can be divided into uni- (UCD) and multicentric form (MCD) according to the disease extent. MCD is usually accompanied by the features of a systemic inflammatory response including fever, weight loss, hepatosplenomegaly, ascites, and edema. In these patients, we can also observe elevation of inflammatory parameters and anemia within the laboratory assessment. Based on etiological nature, the CD can be further divided into human herpesvirus-8-associated (HHV8-associated) and idiopathic form. Interleukin 6 (IL-6) plays a central role in the disease pathogenesis. Inhibition of IL-6 has been shown to be an effective treatment modality. Currently, siltuximab, a chimeric monoclonal antibody targeting IL-6, is the only approved treatment for MCD. Its short-term and long-term efficacy and safety have been demonstrated in a few clinical studies.
Keywords:
interleukin 6 – Castleman disease – siltuximab – TAFRO – POEMS – HHV-8
Sources
- Cabot RC, Castleman B, Towne VW. Case 40351. Case records of the Massachusetts General Hospital. N Engl J Med 1954; 251: 396–400.
- Simpson D. Epidemiology of Castleman disease. Hematol Oncol Clin North Am 2018; 32: 1–10.
- Cronin DMP, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 2009; 16: 236–246.
- Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood 2020; 135: 1353–1364.
- Wong RSM. Unicentric Castleman Disease. Hematol Oncol Clin North Am 2018; 32: 65–73.
- van Rhee F, Oksenhendler E, Srkalovic G et al. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv 2020; 4: 6039–6050.
- Fajgenbaum DC, Uldrick TS, Bagg A et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 2017; 129: 1646–1657.
- Sakashita K, Murata K, Takamori M. TAFRO syndrome: current perspectives. J Blood Med 2018; 9: 15–23.
- Dispenzieri A. POEMS syndrome: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol 2021; 96: 872–888.
- Luo Y, Zheng SG. Hall of fame among pro-inflammatory cytokines: Interleukin-6 gene and its transcriptional regulation mechanisms. Front Immunol 2016; 7: 604.
- Kaur S, Bansal Y, Kumar R, Bansal G. A panoramic review of IL-6: structure, pathophysiological roles and inhibitors. Bioorg Med Chem 2020; 28: 115327.
- Tanaka T, Narazaki M, Kishimoto T. Il-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014; 6: a016295.
- van Rhee F, Voorhees P, Dispenzieri A et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 2018; 132: 2115–2124.
- Doubek M, Mayer J (eds.). Léčebné postupy v hematologii – aktualizace 2022. Česká hematologická společnost ČLS JEP 2022: 416–438.
- van Rhee F, Wong RS, Munshi N et al. Siltuximab for multicentric Castleman disease: A randomised, double-blind, placebo-controlled trial. Lancet Oncol 2014; 15: 966–974.
- Sitenga J, Aird G, Ahmed A, Silberstein PT. Impact of siltuximab on patient-related outcomes in multicentric Castleman disease. Patient Relat Outcome Meas 2018; 57: 1149–1156.
- van Rhee F, Casper C, Voorhees PM et al. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. Lancet Haematol 2020; 7: e209–e217.
- Morra DE, Pierson SK, Shilling D et al. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. Br J Haematol 2019; 184: 232–241.
- Castell JV, Gómez-Lechón MJ, David M et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989; 242: 237–239.
- Vadhan-Raj S, Zhou X, Bueso-Ramos CE et al. Interleukin-6, hepcidin, and other biomarkers in anemia of chronic disease (ACD) and chemotherapy-induced anemia (CIA): potential therapeutic targets. Blood 2012; 120: 2086.
- Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010; 22: 347–352.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
2023 Issue 2-3
Most read in this issue
- Seasonal and weekly fluctuations in alcohol use in the Czech Republic
- Physicians’ experiences of intercultural differences in communication with Ukrainian refugees during the Russian-Ukrainian armed conflict
- The dementia-friendly community and its implications for healthcare
- Hepatocellular carcinoma, multiple primary neoplasia, and their association with diabetes type 2